COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies
Biometrics · 2025
DOI: 10.1093/biomtc/ujaf077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biometrics, 2025. Verfasst von Xiaohan Chi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NLM NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
In cancer treatment, the development of combination therapies requires demonstrating the contribution of each individual drug and optimizing the dose during early-phase trials. This necessitates a large sample size, presenting formidable obstacles for drug developers. To address this issue, we propose a 2-stage randomized phase II design that seamlessly integrates combination dose optimization with component contribution assessment. In stage 1, the optimal combination dose is determined by maximizing the risk–benefit tradeoff across multiple candidate combination doses. In stage 2, a multi-arm randomized phase is initiated to evaluate the contribution of each component within the combination therapy. To increase trial efficiency and reduce the sample size, efficacy data from both stages are adaptively combined using a Bayesian logistic regression model with a spike-and-slab prior. The sample size and decision cutoffs of the proposed design are systematically determined based on a novel calibration procedure to achieve desired operating characteristics. Extensive simulation studies show that the proposed design achieves the dual goals of dose optimization and contribution assessment, while yielding substantial sample size savings compared to competing designs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
ORCID-Profile: Xiaohan Chi, Ruitao Lin, Ying Yuan
Förderung
- NLM NIH HHS
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Chi, X., Lin, R., & Yuan, Y. (2025). COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies. Biometrics. https://doi.org/10.1093/biomtc/ujaf077
Vancouver
Chi X, Lin R, Yuan Y. COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies. Biometrics. 2025. doi:10.1093/biomtc/ujaf077
BibTeX
@article{Chi2025,
author = {Chi, Xiaohan and Lin, Ruitao and Yuan, Ying},
title = {COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies},
journal = {Biometrics},
year = {2025},
doi = {10.1093/biomtc/ujaf077}
}
EUVIMED